114 Reason 3 O O
Epidemiological Reason 3 O O
Report Reason 3 O O
An Reason 3 O O
Epidemiological Reason 3 O O
Study Reason 3 O O
on Reason 3 O O
Japanese Reason 3 O O
Autism Reason 3 O O
concerning Reason 3 O O
Routine Reason 3 O O
Childhood Reason 3 O O
Immunization Reason 3 O O
International Reason 3 O O
Cooperation, Reason 3 O O
Japan Reason 3 O O
International Reason 3 O O
Cooperation Reason 3 O O
Agency, Reason 3 O O
Tokyo Reason 3 O O
162-8433, Reason 3 O O
1Tokyo Reason 3 O O
Metropolitan Reason 3 O O
Umegaoka Reason 3 O O
Hospital, Reason 3 O O
Tokyo Reason 3 O O
156-0043, Reason 3 O O
2Wada Reason 3 O O
Pediatric Reason 3 O O
Clinic, Reason 3 O O
Tokyo Reason 3 O O
121-0812 Reason 3 O O
and Reason 3 O O
3Infectious Reason 3 O O
Disease Reason 3 O O
Surveillance Reason 3 O O
Center, Reason 3 O O
National Reason 3 O O
Institute Reason 3 O O
of Reason 3 O O
Infectious Reason 3 O O
Diseases, Reason 3 O O
Tokyo Reason 3 O O
162-8640, Reason 3 O O
Japan Reason 3 O O
(Received Reason 3 O O
February Reason 3 O O
21, Reason 3 O O
2003. Reason 3 O O
Accepted Reason 3 O O
May Reason 3 O O
16, Reason 3 O O
2003 Reason 3 O O
) Reason 3 O O
SUMMARY Reason 3 O O
: Reason 3 O O
To Reason 3 O O
assess Reason 3 O O
the Reason 3 O O
causal Reason 3 O O
association Reason 3 O O
of Reason 3 O O
autism Reason 3 O O
with Reason 3 O O
measles, Reason 3 O O
mumps, Reason 3 O O
and Reason 3 O O
rubella Reason 3 O O
(MMR) Reason 3 O O
vaccine Reason 3 O O
versus Reason 3 O O
and Reason 3 O O
rubella Reason 3 O O
immunization, Reason 3 O O
a Reason 3 O O
1:2 Reason 3 O O
sex-adjusted Reason 3 O O
logistic Reason 3 O O
regression Reason 3 O O
analysis Reason 3 O O
was Reason 3 O O
conducted Reason 3 O O
using Reason 3 O O
data Reason 3 O O
on Reason 3 O O
subjects Reason 3 O O
who Reason 3 O O
were Reason 3 O O
growing Reason 3 O O
up Reason 3 O O
in Reason 3 O O
the Reason 3 O O
Tokyo Reason 3 O O
area Reason 3 O O
between Reason 3 O O
1988 Reason 3 O O
and Reason 3 O O
1992. Reason 3 O O
When Reason 3 O O
MMR Reason 3 O O
immunization Reason 3 O O
was Reason 3 O O
used Reason 3 O O
as Reason 3 O O
a Reason 3 O O
reference, Reason 3 O O
monovalent Reason 3 O O
measles Reason 3 O O
immunization Reason 3 O O
(odds Reason 3 O O
ratio Reason 3 O O
[OR] Reason 3 O O
= Reason 3 O O
5.33,99% Reason 3 O O
confidence Reason 3 O O
CI: Reason 3 O O
1.30-56.4) Reason 3 O O
with Reason 3 O O
development Reason 3 O O
of Reason 3 O O
autistic Reason 3 O O
spectrum Reason 3 O O
disorders Reason 3 O O
(ASD) Reason 3 O O
were Reason 3 O O
significantly Reason 3 O O
increased. Reason 3 O O
These Reason 3 O O
results Reason 3 O O
suggest Reason 3 O O
a Reason 3 O O
decreased Reason 3 O O
risk Reason 3 O O
of Reason 3 O O
developing Reason 3 O O
ASD Reason 3 O O
with Reason 3 O O
MMR Reason 3 O O
compared Reason 3 O O
tomonovalent Reason 3 O O
antigens. Reason 3 O O
However, Reason 3 O O
our Reason 3 O O
findings Reason 3 O O
may Reason 3 O O
reflect Reason 3 O O
potential Reason 3 O O
selection Reason 3 O O
bias Reason 3 O O
due Reason 3 O O
to Reason 3 O O
requiring Reason 3 O O
written Reason 3 O O
consent, Reason 3 O O
possible Reason 3 O O
delayed Reason 3 O O
vaccination Reason 3 O O
in Reason 3 O O
suspected Reason 3 O O
autism Reason 3 O O
cases, Reason 3 O O
and Reason 3 O O
small Reason 3 O O
sample Reason 3 O O
size Reason 3 O O
(case Reason 3 O O
= Reason 3 O O
21). Reason 3 O O
For O O O O
the O O O O
case O O O O
group O O O O
and O O O O
the O O O O
control O O O O
group, O O O O
immunization O O O O
completeness O O O O
rate O O O O
of O O O O
each O O O O
antigen, O O O O
regardless O O O O
of O O O O
the O O O O
timing O O O O
of O O O O
immunization,was O O O O
90.5% O O O O
versus O O O O
100% O O O O
in O O O O
measles, O O O O
83.3% O O O O
< O O O O
0.01), O O O O
14.3% O O O O
versus O O O O
in O O O O
90.5% O O O O
in O O O O
polio2, O O O O
100% O O O O
versus O O O O
97.6% O O O O
in O O O O
Diphtheria O O O O
(D), O O O O
pertussis, O O O O
and O O O O
tetanus O O O O
(T) O O O O
3, O O O O
85.7% O O O O
versus O O O O
66.7% O O O O
in O O O O
DT, O O O O
95.2% O O O O
versus O O O O
92.9% O O O O
in O O O O
Japanese O O O O
encephalitis O O O O
3 O O O O
( O O O O
P<0.01). O O O O
Only O O O O
two O O O O
case O O O O
subjects O O O O
and O O O O
four O O O O
control O O O O
subjects O O O O
received O O O O
their O O O O
measles, O O O O
mumps, O O O O
and O O O O
rubella O O O O
immunizations O O O O
separately, O O O O
suggesting O O O O
that O O O O
few O O O O
Japanese O O O O
parents O O O O
might O O O O
have O O O O
had O O O O
concerns O O O O
about O O O O
the O O O O
safety O O O O
of O O O O
MMR O O O O
vaccine. O O O O
A O O O O
nation-wide O O O O
study O O O O
would O O O O
be O O O O
a O O O O
practical O O O O
measure O O O O
toscientifically O O O O
judge O O O O
the O O O O
safety O O O O
of O O O O
MMR O O O O
and O O O O
other O O O O
routine O O O O
childhood O O O O
immunizations. O O O O
Wakefield Reason 2 O O
andcolleagues Reason 2 O O
speculated Reason 2 O O
that Reason 2 O O
persistent Reason 2 O O
measles Reason 2 O O
virus Reason 2 O O
infection Reason 2 O O
of Reason 2 O O
the Reason 2 O O
gastrointestinal Reason 2 O O
tract Reason 2 O O
could Reason 2 O O
have Reason 2 O O
resulted Reason 2 O O
in Reason 2 O O
ileocolonic Reason 2 O O
lymphonodular Reason 2 O O
hyperplasia Reason 2 O O
that Reason 2 O O
allowed Reason 2 O O
gastrointestinalabsorption Reason 2 O O
of Reason 2 O O
toxic Reason 2 O O
neuropeptides, Reason 2 O O
which Reason 2 O O
then Reason 2 O O
caused Reason 2 O O
central Reason 2 O O
nervous Reason 2 O O
system Reason 2 O O
damage Reason 2 O O
followed Reason 2 O O
by Reason 2 O O
neurodevelopmental Reason 2 O O
regression Reason 2 O O
(1). Reason 2 O O
The O O O O
authors O O O O
hypothesized O O O O
that O O O O
combinedmeasles, O O O O
mumps, O O O O
and O O O O
rubella O O O O
(MMR) O O O O
vaccine O O O O
might O O O O
cause O O O O
autism, O O O O
and O O O O
recommended O O O O
alternative O O O O
use O O O O
of O O O O
a O O O O
monovalent O O O O
measles O O O O
vaccine. O O O O
However, O O O O
to O O O O
date, O O O O
no O O O O
published O O O O
report O O O O
hassupported O O O O
their O O O O
hypothesis O O O O
(2) O O O O
